SCA
ABBV icon

Snowden Capital Advisors’s AbbVie ABBV Stock Holding History

Snowden Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.7M Sell
118,163
-539
-0.5% -$120K 0.68% 23
2025
Q4 		$27.1M Buy
118,702
+24,145
+26% +$5.5M 0.7% 21
2025
Q3 		$21.9M Sell
94,557
-1,483
-2% -$302K 0.6% 25
2025
Q2 		$17.8M Sell
96,040
-249
-0.3% -$46.3K 0.53% 28
2025
Q1 		$20.2M Sell
96,289
-2,047
-2% -$398K 0.65% 22
2024
Q4 		$17.5M Sell
98,336
-18,142
-16% -$3.34M 0.54% 27
2024
Q3 		$23M Sell
116,478
-11,139
-9% -$2.08M 0.68% 18
2024
Q2 		$21.9M Sell
127,617
-14,228
-10% -$2.36M 0.65% 20
2024
Q1 		$25.8M Buy
141,845
+16,394
+13% +$2.83M 0.81% 11
2023
Q4 		$19.4M Sell
125,451
-939
-0.7% -$137K 0.74% 11
2023
Q3 		$18.8M Sell
126,390
-2,939
-2% -$431K 0.8% 10
2023
Q2 		$17.4M Buy
129,329
+5,343
+4% +$784K 0.62% 24
2023
Q1 		$19.8M Buy
123,986
+2,112
+2% +$323K 0.77% 13
2022
Q4 		$19.7M Buy
121,874
+3,960
+3% +$607K 0.83% 10
2022
Q3 		$15.8M Buy
117,914
+21,265
+22% +$3.05M 0.72% 17
2022
Q2 		$14.8M Buy
96,649
+5,939
+7% +$908K 0.66% 18
2022
Q1 		$14.7M Buy
90,710
+23,792
+36% +$3.46M 0.59% 26
2021
Q4 		$9.06M Sell
66,918
-7,700
-10% -$910K 0.46% 45
2021
Q3 		$8.05M Buy
74,618
+6,009
+9% +$687K 0.4% 51
2021
Q2 		$7.73M Buy
68,609
+6,698
+11% +$754K 0.39% 53
2021
Q1 		$6.7M Buy
61,911
+8,988
+17% +$961K 0.38% 58
2020
Q4 		$5.67M Buy
52,923
+1,629
+3% +$157K 0.37% 67
2020
Q3 		$4.49M Sell
51,294
-1,062
-2% -$100K 0.36% 79
2020
Q2 		$5.14M Buy
52,356
+8,531
+19% +$751K 0.44% 63
2020
Q1 		$3.34M Buy
43,825
+2,681
+7% +$228K 0.36% 76
2019
Q4 		$3.64M Buy
41,144
+20,986
+104% +$1.74M 0.32% 93
2019
Q3 		$1.53M Sell
20,158
-1,729
-8% -$119K 0.15% 198
2019
Q2 		$1.59M Buy
21,887
+851
+4% +$66.9K 0.16% 190
2019
Q1 		$1.7M Buy
21,036
+176
+0.8% +$14.4K 0.19% 180
2018
Q4 		$1.92M Sell
20,860
-2,594
-11% -$228K 0.25% 144
2018
Q3 		$2.22M Buy
23,454
+2,027
+9% +$192K 0.25% 128
2018
Q2 		$1.99M Buy
21,427
+832
+4% +$81.3K 0.26% 124
2018
Q1 		$1.95M Buy
20,595
+2,360
+13% +$259K 0.29% 117
2017
Q4 		$1.76M Buy
18,235
+3,147
+21% +$297K 0.25% 132
2017
Q3 		$1.34M Buy
15,088
+2,564
+20% +$195K 0.22% 150
2017
Q2 		$908K Buy
12,524
+897
+8% +$60.3K 0.17% 173
2017
Q1 		$758K Buy
11,627
+2,578
+28% +$162K 0.17% 178
2016
Q4 		$567K Buy
9,049
+2,074
+30% +$127K 0.14% 184
2016
Q3 		$440K Sell
6,975
-7,312
-51% -$473K 0.12% 214
2016
Q2 		$884K Buy
14,287
+7,181
+101% +$438K 0.27% 135
2016
Q1 		$406K Buy
+7,106
New +$396K 0.14% 189

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Snowden Capital Advisors's ABBV Position: Q1 2026 in Review

Snowden Capital Advisors reduced its AbbVie (ABBV) stake by 0.45% in Q1 2026, selling an estimated $120K and leaving 118,163 shares worth $25.7M. The position accounts for 0.68% of the portfolio, ranked #23.

Snowden Capital Advisors first reported a position in ABBV in Q1 2016 and has held it in 41 quarters since. The position peaked at $27.1M in Q4 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Snowden Capital Advisors held 118,163 shares of AbbVie worth $25.7M as of Q1 2026.
  • Snowden Capital Advisors sold 539 AbbVie shares in Q1 2026, an estimated $120K.
  • AbbVie made up 0.68% of Snowden Capital Advisors's portfolio in Q1 2026, its #23 holding.
  • Snowden Capital Advisors first reported a position in AbbVie in Q1 2016 and has held it in 41 quarters since.
  • Snowden Capital Advisors's AbbVie position peaked at $27.1M in Q4 2025.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.